Ginkgo Bioworks DNA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Ginkgo Bioworks’s reported figures.
Based on trailing twelve months.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's return on equity?
- Ginkgo Bioworks (DNA) reported return on equity of -55.8% in Q1 2026.
- How has Ginkgo Bioworks's return on equity changed year-over-year?
- Ginkgo Bioworks's return on equity increased by 3.3% year-over-year, from -57.8% to -55.8%.
- What is the long-term trend for Ginkgo Bioworks's return on equity?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's return on equity has grown at a 14.1% compound annual growth rate (CAGR), from -26.4% to -51.1%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.